Earnings Call Summary | Palatin Technologies(PTN.US) Q3 2024 Earnings Conference
Earnings Call Summary | Palatin Technologies(PTN.US) Q3 2024 Earnings Conference
The following is a summary of the Palatin Technologies, Inc. (PTN) Q3 2024 Earnings Call Transcript:
以下是帕拉丁科技公司（PTN）2024年第三季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Palatin Technologies reported no product sales in the quarter ended March 31, 2024 due to the sale of Vyleesi's worldwide rights.
Total operating expenses were $9.2 million, an increase primarily due to heightened spending on Melanocortin receptor programs.
The net cash used in operations was $8.6 million, an increase mostly from changes in working capital.
Net loss for the quarter was $8.4 million or $0.53 per share.
As of March 31, 2024, the company's cash, cash equivalents and marketable securities totaled to $10 million.
帕拉丁科技公司報告稱，由於出售了Vyleesi的全球版權，截至2024年3月31日的季度沒有產品銷售。
總運營支出爲920萬美元，增長主要是由於黑色皮質素受體項目支出增加。
運營中使用的淨現金爲860萬美元，主要來自營運資金的變化。
該季度的淨虧損爲840萬美元，合每股虧損0.53美元。
截至2024年3月31日，該公司的現金、現金等價物和有價證券總額爲1000萬美元。
Business Progress:
業務進展：
Palatin has focused on the biology and chemistry of the Melanocortin system to develop selective Melanocortin agonists.
The company has three clinical programs based on Melanocortin agonists and plans to start enrollment in two new clinical programs by mid-2024.
Positive results were reported for PL9643 Phase 3 MELODY-1 dry eye disease clinical study.
A Phase 2 obesity study and a Phase 2 study for treating erectile dysfunction are expected to start this year.
Current financial resources are expected to fund operating expenses well into the second half of calendar year 2024.
帕拉汀專注於黑皮質素系統的生物學和化學，以開發選擇性黑皮質素激動劑。
該公司有三個基於黑皮質素激動劑的臨床項目，並計劃在2024年中期之前開始註冊兩個新的臨床項目。
PL9643 3 期 MELODY-1 乾眼病臨床研究報告了陽性結果。
2期肥胖研究和治療勃起功能障礙的2期研究預計將於今年開始。
預計目前的財務資源將爲2024日曆年下半年的運營費用提供資金。
More details: Palatin Technologies IR
更多詳情： 帕拉丁科技 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。